- Home
- SAVA vs SVII Comparison
SAVA vs SVII Comparison
Compare SAVA & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SVII
- Stock Information
- Founded
- SAVA 1998
- SVII 2021
- Country
- SAVA United States
- SVII United States
- Employees
- SAVA N/A
- SVII N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- SAVA Health Care
- SVII Finance
- Exchange
- SAVA Nasdaq
- SVII Nasdaq
- Market Cap
- SAVA 102.4M
- SVII 119.4M
- IPO Year
- SAVA N/A
- SVII 2022
- Fundamental
- Price
- SAVA $2.11
- SVII $12.05
- Analyst Decision
- SAVA Hold
- SVII
- Analyst Count
- SAVA 1
- SVII 0
- Target Price
- SAVA $2.00
- SVII N/A
- AVG Volume (30 Days)
- SAVA 517.9K
- SVII 23.5K
- Earning Date
- SAVA 11-06-2025
- SVII 01-01-0001
- Dividend Yield
- SAVA N/A
- SVII N/A
- EPS Growth
- SAVA N/A
- SVII N/A
- EPS
- SAVA N/A
- SVII 0.17
- Revenue
- SAVA N/A
- SVII N/A
- Revenue This Year
- SAVA N/A
- SVII N/A
- Revenue Next Year
- SAVA N/A
- SVII N/A
- P/E Ratio
- SAVA N/A
- SVII $72.64
- Revenue Growth
- SAVA N/A
- SVII N/A
- 52 Week Low
- SAVA $1.15
- SVII $11.20
- 52 Week High
- SAVA $33.98
- SVII $12.74
- Technical
- Relative Strength Index (RSI)
- SAVA 44.15
- SVII 51.87
- Support Level
- SAVA $2.12
- SVII $11.91
- Resistance Level
- SAVA $2.19
- SVII $12.35
- Average True Range (ATR)
- SAVA 0.10
- SVII 0.11
- MACD
- SAVA -0.02
- SVII -0.01
- Stochastic Oscillator
- SAVA 6.45
- SVII 31.84
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.